Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 8:8:23-30.
doi: 10.4137/CMRH.S14498. eCollection 2014.

Management of Vaginal Atrophy: Implications from the REVIVE Survey

Susan Wysocki  1 , Sheryl Kingsberg  2 , Michael Krychman  3
Affiliations
Review

Management of Vaginal Atrophy: Implications from the REVIVE Survey

Susan Wysocki et al. Clin Med Insights Reprod Health. .

Abstract

Vulvar and vaginal atrophy (VVA) is a chronic and progressive medical condition common in postmenopausal women. Symptoms of VVA such as dyspareunia, vaginal dryness, irritation, and itching can negatively impact sexual function and quality of life. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey assessed knowledge about VVA and recorded attitudes about interactions with healthcare providers (HCPs) and available treatment options for VVA. The REVIVE survey identified unmet needs of women with VVA symptoms such as poor understanding of the condition, poor communication with HCPs despite the presence of vaginal symptoms, and concerns about the safety, convenience, and efficacy of available VVA treatments. HCPs can address these unmet needs by proactively identifying patients with VVA and educating them about the condition as well as discussing treatment preferences and available therapies for VVA.

Keywords: REVIVE survey; postmenopausal; treatment strategies; vulvar and vaginal atrophy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Images of (A) healthy vaginal tissue and (B) atrophic vaginal tissue.
Figure 2
Figure 2
Suggested approach to treating postmenopausal women at risk for VVA. Notes: aConfirmed by visual examination of the vagina. bIf OTC products are tried initially, consider providing a prescription that the patient can have on hand if the OTC products are found to be inadequate; this may help to avoid a delay in treatment.
See this image and copyright information in PMC

References

    1. The North American Menopause Society Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902. - PubMed
    1. Johnston SL, Farrell SA, Bouchard C, et al. The detection and management of vaginal atrophy. J Obstet Gynaecol Can. 2004;26(5):503–515. - PubMed
    1. US Department of Commerce . Age and sex composition: 2010. Washington, DC: US Census Bureau; (Report No.: C2010BR-03-2011).
    1. Gass ML, Cochrane BB, Larson JC, et al. Patterns and predictors of sexual activity among women in the hormone therapy trials of the Women’s Health Initiative. Menopause. 2011;18(11):1160–1171. - PubMed
    1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537–544. - PubMed